Senseonics Announces Initiation of European Commercial Efforts by Partner Ascensia Diabetes Care
February 01 2021 - 8:00AM
Business Wire
Senseonics Holdings, Inc. (NYSE American: SENS), a medical
technology company focused on the development and commercialization
of long-term, implantable continuous glucose monitoring (CGM)
systems for people with diabetes, today announced that Ascensia
Diabetes Care (Ascensia) has commenced sales and marketing
activities for the Eversense® XL CGM system in key European markets
as of today, as part of their strategic partnership announced in
August, 2020.
“Today, we are extremely excited to see Ascensia, a global
leader in the diabetes technology space, begin distribution of the
Eversense XL in these key European markets. We are confident our
shared goal of bringing our advanced long-term solution to more
people with diabetes will be accomplished through Ascensia’s high
level of commitment to our products and to patients and healthcare
providers,” said Tim Goodnow, PhD, President and CEO of Senseonics.
“Today further strengthens our collaboration and shows the
commitment of our combined organizations to provide patients with
an implantable sensor that gives them continuous glucose readings
for up to 180 days. Ascensia’s global infrastructure and strong
commercial experience alongside our focus on innovation, product
development and production will enhance value for all our
stakeholders.”
Under terms of the commercial agreement, today Ascensia
initiates distribution of the Eversense XL System in Germany,
Italy, The Netherlands, Poland, Spain and Switzerland. In the US,
Ascensia is already providing sales support for the original
Eversense® CGM system.
Ascensia Diabetes Care is a global specialist diabetes care
company that is dedicated to helping people living with diabetes.
It is a leader in the blood glucose monitoring market with its
CONTOUR portfolio of systems that are known for their accuracy and
ease of use. Ascensia markets its devices in over 125 countries
across the world. The Switzerland based company is owned by PHC
Holdings Corporation Ltd, a KKR portfolio company.
Eversense XL is the only CGM providing continuous glucose
readings for up to 180 days with a single sensor in persons age 18
and older in the European market. The Eversense CGM System in the
US provides continuous glucose readings for up to 90 days with a
single sensor in persons age 18 and older. Inserted under the skin
in a simple in-office procedure, Eversense XL gives users the
freedom from weekly or bi-weekly self-insertions. Designed with the
patient in mind, the Eversense® system has a removable transmitter
that provides discretion and flexibility, with the added
reassurance of on-body vibratory alerts, to inform users when their
glucose level is outside their low or high settings. The system is
accurate throughout its sensor life with a MARD of 9.4%1. The
Eversense® Mobile app allows for real-time monitoring and
management, enables users to view their data on their smart phone
and share retrospective data from the Data Management System with
their HCPs. In addition, through the accompanying Eversense® NOW
caregiver app, up to five other people can remotely view a user’s
real-time readings and alerts.
About Eversense
The Eversense® Continuous Glucose Monitoring (CGM) System is
indicated for continually measuring glucose levels in persons age
18 and older with diabetes for up to 90 days in the US and the
Eversense XL provides glucose readings for up to 180 days outside
the US. The system is indicated for use to replace fingerstick
blood glucose (BG) measurements for diabetes treatment decisions.
Fingerstick BG measurements are still required for calibration
twice per day, and when symptoms do not match CGM information or
when taking medications of the tetracycline class. The sensor
insertion and removal procedures are performed by a health care
provider. The Eversense CGM System is a prescription device;
patients should talk to their health care provider to learn more.
For important safety information, see
https://eversensediabetes.com/safety-info/.
About Senseonics
Senseonics Holdings, Inc. is a medical technology company
focused on the design, development and commercialization of
transformational glucose monitoring products designed to help
people with diabetes confidently live their lives with ease.
Senseonics' CGM systems, Eversense® and Eversense® XL, include a
small sensor inserted completely under the skin that communicates
with a smart transmitter worn over the sensor. The glucose data are
automatically sent every 5 minutes to a mobile app on the user's
smartphone.
- Aronson R et al. First assessment of the performance of an
implantable continuous glucose monitoring system through 180 days
in a primarily adolescent population with type 1 diabetes. Diabetes
Obes Metab 2019;21(7):1689-1694
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210201005263/en/
Senseonics Investor Contact: Lynn Lewis or Philip Taylor
Investor Relations 415-937-5406 investors@senseonics.com
Senseonics Media Contact: Mirasol Panlilio 301-556-1631
Mirasol.panlilio@senseonics.com
Senseonics (AMEX:SENS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Senseonics (AMEX:SENS)
Historical Stock Chart
From Sep 2023 to Sep 2024